| abstract |
The invention provides highly effective combinations of a compound of formula A (a selective PI3Kδ inhibitor) and anti-CD20 antibodies for treating and alleviating diseases and disorders mediated by PI3Kδ and / or CD20. In particular, this combination can be used to treat cancer and autoimmune diseases. More specifically, the invention provides a combination of a compound of formula (A) or stereoisomers thereof and ublitituximab for the treatment and / or alleviation of hematological malignant diseases, such as leukemia and lymphoma. |